As a GLP-1 receptor agonist, semaglutide mimics the actions of endogenous GLP-1 but with one critical engineering advantage: while native GLP-1 has a biological half-life of only a few minutes before being cleaved by the enzyme DPP-4, semaglutide achieves a half-life of approximately seven days through structural modifications that include an Aib amino acid substitution at position 8 (blocking DPP-4 recognition) and a C18 fatty acid chain attached via a linker, which enables reversible binding to albumin in the bloodstream
Additionally, lixisenatide is not the only GLP-1 receptor agonist with potential therapeutic applications for Parkinson's at least six other similar medications are currently being evaluated as a potential PD treatment
YangSYCastellaniCALongchampsRJPillalamarriVKO'RourkeBGuallarEet al
CICM 2025 Aesthetic Dermatology: Evidence-Based Medicine is an annual event that BSL doctors never miss, in order to stay updated with knowledge and research on dermatological treatments including acne, melasma, freckles, hair loss, and scalp issues as well as aesthetic procedures such as facial, neck, and body skin tightening, weight loss, and body contouring, all aimed at achieving healthy and youthful-looking skin
